Cynara scolymus/Globe Artichoke/Artichoke Extract / P53 Cancer Research Results

Cynara scolymus - Globe Artichoke / Artichoke Extract,, Artichoke leaf extract

Type: Botanical extract / polyphenol-rich medicinal plant

Active Constituents: Cynarin, chlorogenic acid, caffeoylquinic acids, luteolin, apigenin, and related flavonoids and phenolic compounds.

Function: Cynara scolymus exhibits antioxidant, anti-inflammatory, hepatoprotective, lipid-modulating, metabolic, and cytoprotective effects. Artichoke extracts can modulate oxidative stress, inflammatory signaling, apoptosis, and cellular metabolism.

Cancer: Experimental studies indicate antiproliferative, pro-apoptotic, antioxidant, and anti-inflammatory effects in multiple cancer cell models, with potential modulation of cell-cycle and survival pathways.

Alzheimer's Disease: Preclinical evidence suggests neuroprotective effects through antioxidant, anti-inflammatory, and cholinergic mechanisms, but the evidence base is less developed than for its metabolic and hepatic effects.

Cynara scolymus — globe artichoke, commonly used medicinally as artichoke leaf extract (ALE), is a polyphenol- and sesquiterpene-lactone-rich botanical preparation derived primarily from the leaves of Cynara cardunculus L. subsp. scolymus, historically also designated Cynara scolymus L. It is classified as a botanical extract / herbal medicinal product rather than a single defined drug. Common abbreviations are CS and ALE. Major constituents include chlorogenic acid and other caffeoylquinic acids, cynarin, luteolin glycosides, apigenin derivatives, and the sesquiterpene lactone cynaropicrin; their concentrations vary substantially with plant part, cultivar, extraction method, and standardization. Artichoke leaf preparations have established traditional gastrointestinal use and human clinical investigation for dyslipidemia and metabolic/liver disorders, whereas anticancer activity remains predominantly preclinical.

Primary mechanisms (ranked):

1. Induction of mitochondrial apoptosis through ↑BAX, ↓BCL-2, mitochondrial dysfunction, and caspase-9/caspase activation.
2. Cell-cycle arrest and durable growth suppression, including G2/M arrest and p16/p21-associated cellular senescence.
3. Context-dependent pro-oxidant ROS accumulation in cancer cells, contributing to apoptosis, senescence, DNA damage, and chemosensitization.
4. Suppression of proliferative and inflammatory survival signaling, including ↓NF-κB activity in susceptible cancer models.
5. Suppression of cancer-cell invasion and metastatic phenotype in breast-cancer models.
6. FEN1 downregulation and increased DNA-damage susceptibility, enhancing sensitivity to DNA-damaging chemotherapy such as paclitaxel in preclinical breast-cancer models.
7. Antioxidant and cytoprotective activity in non-malignant tissues through polyphenol-mediated reduction of oxidative injury; this contrasts with the pro-oxidant response observed in some cancer models.

Bioavailability / PK relevance: Artichoke extract is a complex mixture rather than a single systemically delivered compound. Human pharmacokinetic studies demonstrate absorption and extensive metabolism of caffeoylquinic acids and flavonoids, with circulating metabolites such as caffeic/dihydrocaffeic-acid derivatives and conjugated flavonoids likely contributing to biological activity. Parent polyphenol exposure is relatively low and extensively transformed by intestinal, hepatic, and microbial metabolism. Extract composition and standardization are therefore major determinants of exposure.

In-vitro vs systemic exposure relevance: Many anticancer experiments use whole artichoke extracts at concentrations in the tens to hundreds of µg/mL range or prolonged cellular exposure. These conditions cannot be assumed to reproduce concentrations of intact extract constituents in human tumors after oral supplementation. Human circulating concentrations of individual absorbed polyphenols are generally in the submicromolar-to-low-micromolar range and are dominated by metabolites; consequently, direct extrapolation of cytotoxic in-vitro concentrations to oral systemic anticancer activity is not justified.

Clinical evidence status: Cancer: preclinical only; no established anticancer efficacy in humans and no validated role as cancer therapy or adjunct treatment. Non-cancer indications: multiple small randomized human trials and meta-analyses report effects on lipid parameters, and clinical studies have evaluated metabolic and hepatic outcomes. European herbal-medicine recognition is based principally on traditional use for dyspeptic gastrointestinal complaints rather than cancer treatment.

Safety / translation constraints: Artichoke leaf preparations are generally well tolerated in short-term human studies, but gastrointestinal adverse effects and allergic reactions can occur. Avoid in patients with hypersensitivity to artichoke or other Asteraceae plants. Because artichoke can stimulate bile secretion, bile-duct obstruction and cholangitis are important contraindications, and gallstones or other biliary disorders warrant medical assessment. Extract-to-extract chemical heterogeneity and the large exposure gap between many cell-culture experiments and oral human dosing are major constraints on anticancer translation.

Cancer-Relevant Mechanisms of Cynara scolymus Extract

P: 0–30 min     R: 30 min–3 hr     G: >3 hr